Cassava Sciences SAVA recently suffered yet another setback, which raises concern regarding its prospects. Last week, the company announced that the phase III study REFOCUS-ALZ on lead pipeline ...

A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling pressure. The stock has declined 83.9% over the past four weeks. However, given the fact that it is now in ...

Both gravel bikes and electric bikes are becoming more popular, so it should come as no surprise that we're seeing an increasing number of gravel ebikes. One of the latest, the E-Flash, features a ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, simufilam, failed to meet the prespecified co-primary endpoints in the second ...

Like many Americans, I’m constantly overwhelmed by stress. It leads to restless nights, unproductive afternoons and overall feelings of dread. When I was introduced to Tersa’s $10,000 Sava immersive ...

I love SAVA’s concept— curated cannabis. It means something to me to learn from others. I don't know everything, far from. So, when I discovered the "curated" approach that SAVA takes, they certainly ...

The ST. SAVA SERBIAN ORTHODOX CHURCH CONTROVERSY (1963-75) over control of church property and control by a hierarchical form of church government split Cleveland's SERBIAN community. An ...

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is ...